Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4103/ijn.IJN_2_16 http://scihub22266oqcxt.onion/10.4103/ijn.IJN_2_16 C5830807!5830807!29515299     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Indian+J+Nephrol 2018 ; 28 (1): 35-40 Nephropedia Template TP {{tp|p=29515299|t=2018. Mycophenolate versus Cyclophosphamide for Lupus Nephritis |pdf=|usr=}}{{29515299}} gab.com Text Mycophenolate versus Cyclophosphamide for Lupus Nephritis JO: Indian J Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=29515299 #FOAvip Systemic lupus erythematosus is common in our country, and renal involvement is an important cause of chronic kidney disease. This study was aimed at comparing the three regimens, i.e., cyclophosphamide-based regimes (low dose and high dose) and mycophenolate mofetil (MMF)-based regime and determining if cyclophosphamide (CPM)-based regime can be an effective, safe, and cheap alternative to MMF-based regime in a resource-limited setting. Out of 144 patients, females constituted 89%. Nephrotic nephritic presentation was the most common. Rapidly progressive renal failure was seen in in 42 (29.1%) patients. Class IV was the most common 66 (45.8%) histological class. Crescentic glomerulonephritis was seen in 18 (12.5%). Overall remission (complete + partial) at 6 months was seen in 71.4% in National Institute of Health regime, 65% in European lupus nephritis trial protocol and 72.9% in MMF regime. End-stage renal disease and switching to other therapies were comparable among the three groups. Although infections were more with CPM, the difference was not statistically significant. CPM-based therapies were associated with a significantly lower cost. Twit Text FOAVip Mycophenolate versus Cyclophosphamide for Lupus Nephritis ????Indian J Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=29515299 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29515299 #FOAvip English Wikipedia <ref>{{Cite pmid|29515299}}</ref> Mycophenolate versus Cyclophosphamide for Lupus Nephritis #MMPMID29515299 Sahay M; Saivani Y; Ismal K; Vali PS Indian J Nephrol 2018[Jan]; 28 (1): 35-40 PMID29515299show ga Systemic lupus erythematosus is common in our country, and renal involvement is an important cause of chronic kidney disease. This study was aimed at comparing the three regimens, i.e., cyclophosphamide-based regimes (low dose and high dose) and mycophenolate mofetil (MMF)-based regime and determining if cyclophosphamide (CPM)-based regime can be an effective, safe, and cheap alternative to MMF-based regime in a resource-limited setting. Out of 144 patients, females constituted 89%. Nephrotic nephritic presentation was the most common. Rapidly progressive renal failure was seen in in 42 (29.1%) patients. Class IV was the most common 66 (45.8%) histological class. Crescentic glomerulonephritis was seen in 18 (12.5%). Overall remission (complete + partial) at 6 months was seen in 71.4% in National Institute of Health regime, 65% in European lupus nephritis trial protocol and 72.9% in MMF regime. End-stage renal disease and switching to other therapies were comparable among the three groups. Although infections were more with CPM, the difference was not statistically significant. CPM-based therapies were associated with a significantly lower cost. äMycophenolate versus Cyclophosphamide for Lupus Nephritis (epmc).pdf DeepDyve Pubget Overpricing